NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057

NCT00712933

CompletedPhase 3

Sponsor: Human Genome Sciences Inc., a GSK Company

Conditions: Systemic Lupus Erythematosus

Interventions: belimumab

Countries: Argentina, Austria, Belgium, Brazil, Canada, Chile, Colombia, Czechia

This is a long-term continuation study to provide continuing treatment to subjects with SLE.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Have completed the HGS 1006-C1056 or HGS 1006-C1057 protocol through the Week 72 or Week 48 visits, respectively.

Exclusion Criteria:

* Have developed any other medical disease or condition that has made the patient unsuitable for this study in the opinion of their physician.

Locations (110)

Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
La Plata, Buenos Aires, Argentina
Rosario, Santa Fe Province, Argentina
San Miguel de Tucumán, Tucumán Province, Argentina
Buenos Aires, Argentina
Buenos Aires, Argentina
Ciudad Autonoma Buenos Aires, Argentina
Vienna, Austria
Liège, Belgium
Salvador, Estado de Bahia, Brazil
Goiânia, Goiás, Brazil
Juiz de Fora, Minas Gerais, Brazil
Recife, Pernambuco, Brazil
Porto Alegre, Rio Grande do Sul, Brazil
São Paulo, São Paulo, Brazil
Campinas, Brazil
Rio de Janeiro, Brazil
São Paulo, Brazil
São Paulo, Brazil
Toronto, Ontario, Canada
Montreal, Quebec, Canada
Viña del Mar, Valparaiso, Chile
Santiago, Chile
Barranquilla, Colombia
Bogotá, Colombia
Bucaramanga, Colombia
Medellín, Colombia
Brno-Bohunice, Czechia
Hradec Králové, Czechia
+ 80 more on CT.gov